These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 24399087)

  • 1. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
    Hill A; Khoo S; Fortunak J; Simmons B; Ford N
    Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
    Hagan LM; Sulkowski MS; Schinazi RF
    Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV direct-acting antiviral agents: the best interferon-free combinations.
    Schinazi R; Halfon P; Marcellin P; Asselah T
    Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
    Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Serfaty L
    Liver Int; 2015 Jan; 35 Suppl 1():18-20. PubMed ID: 25529083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
    Asselah T; Marcellin P
    Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.
    van de Ven N; Fortunak J; Simmons B; Ford N; Cooke GS; Khoo S; Hill A
    Hepatology; 2015 Apr; 61(4):1174-82. PubMed ID: 25482139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicine. Hepatitis C can be cured globally, but at what cost?
    Hill A; Cooke G
    Science; 2014 Jul; 345(6193):141-2. PubMed ID: 25013048
    [No Abstract]   [Full Text] [Related]  

  • 10. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
    Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The price of good health.
    Nat Med; 2014 Apr; 20(4):319. PubMed ID: 24710362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WHO issues guidelines on HCV amid drug cost controversy.
    Slomski A
    JAMA; 2014 Jun; 311(22):2262-3. PubMed ID: 24915242
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
    Campos-Varela I; Straley S; Agudelo EZ; Carlson L; Terrault NA
    Liver Transpl; 2015 Feb; 21(2):272-4. PubMed ID: 25332190
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of HCV patients with cirrhosis with direct acting antivirals.
    Boccaccio V; Bruno S
    Liver Int; 2014 Feb; 34 Suppl 1():38-45. PubMed ID: 24373077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
    Lawitz E; Sulkowski MS; Ghalib R; Rodriguez-Torres M; Younossi ZM; Corregidor A; DeJesus E; Pearlman B; Rabinovitz M; Gitlin N; Lim JK; Pockros PJ; Scott JD; Fevery B; Lambrecht T; Ouwerkerk-Mahadevan S; Callewaert K; Symonds WT; Picchio G; Lindsay KL; Beumont M; Jacobson IM
    Lancet; 2014 Nov; 384(9956):1756-65. PubMed ID: 25078309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faldaprevir for the treatment of hepatitis C.
    Kanda T; Yokosuka O; Omata M
    Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
    Miller MH; Agarwal K; Austin A; Brown A; Barclay ST; Dundas P; Dusheiko GM; Foster GR; Fox R; Hayes PC; Leen C; Millson C; Ryder SD; Tait J; Ustianowski A; Dillon JF; ; ; ; ; ;
    Aliment Pharmacol Ther; 2014 Jun; 39(12):1363-75. PubMed ID: 24754233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.